Rheumatology, Pavillon 2B, Centre Hospitalier Lyon Sud, 165 chemin du grand revoyet 69495, Pierre-Bénite cedex, France.
J Orthop Res. 2012 May;30(5):679-85. doi: 10.1002/jor.21580. Epub 2011 Oct 24.
The aim of the study was to investigate the effect of hyaluronic acid (HA) intra articular injections (IA) on osteoarthritis (OA) biomarkers in patients with knee OA. Prospective open label study. Fifty-one patients with unilateral symptomatic K-OA received IA injections of 2mL of HA on days (D) 1, 7, 14 and were followed 3 months. At D-15 patients were examined and X-rays performed, to exclude patients with bilateral K-OA, or those with more than three symptomatic OA joints. From 15 days (D-15) before the first injection to D90 concomitant therapies were unchanged. Walking pain (WP) on VAS was obtained at each visit. Urine (U) and serum (S) samples were obtained at D-15, D1, D30, and D90. S-C2C, S-Cartilage oligomeric matrix protein, S-HA, S-CS 846 epitope, S-type II collagen propeptide, and U-type II collagen C telopeptide (U-CTX II/creatinin) were assayed. Predictive factors of response were analyzed using logistic regression. Correlations between variables were obtained using Spearman test. Forty-five patients were analyzed. Between D-15 and D1 there was no difference for any biomarkers At D1, WP (SD) was correlated with U-CTX II/creat (p = 0.006). Between D1 and D90: U-CTX II/creat decreased significantly. After adjustment for confounding variables there was a significant correlation between clinical response and U-CTX II/creat variation. U-CTX II and S-HA at baseline were independently predictive of clinical response. This study showed that 90 days after HA IA injections, U-CTX II levels significantly decrease compared to baseline, suggesting a slowdown of type II collagen degradation.
本研究旨在探讨透明质酸(HA)关节内注射(IA)对膝骨关节炎(OA)患者 OA 生物标志物的影响。这是一项前瞻性开放标签研究。51 例单侧症状性膝 OA 患者接受 2mLHAIA 注射,分别于第 1、7、14 天注射,并在 3 个月时进行随访。在第 15 天(D-15),患者接受检查和 X 射线检查,以排除双侧 K-OA 或三个以上有症状的 OA 关节的患者。从第一次注射前 15 天(D-15)到第 90 天,同时进行的治疗保持不变。每次就诊时都记录 VAS 下的步行疼痛(WP)。分别于 D-15、D1、D30 和 D90 时采集尿液(U)和血清(S)样本。检测 S-C2C、S-软骨寡聚基质蛋白、S-HA、S-CS846 表位、S-型 II 胶原前肽和 U-型 II 胶原 C 端肽(U-CTX II/肌酐)。使用逻辑回归分析反应的预测因素。使用 Spearman 检验获得变量之间的相关性。分析了 45 例患者。在 D-15 至 D1 期间,任何生物标志物均无差异。在 D1 时,WP(SD)与 U-CTX II/肌酐呈正相关(p=0.006)。在 D1 至 D90 期间:U-CTX II/肌酐显著降低。在调整混杂变量后,临床反应与 U-CTX II/creat 变化之间存在显著相关性。基线时的 U-CTX II 和 S-HA 是临床反应的独立预测因素。本研究表明,与基线相比,HAIA 注射后 90 天,U-CTX II 水平显著降低,提示 II 型胶原降解速度减慢。